Company profile
Annual Report 2014
LEI
cee stock exchange group
Issuers / Issuers News
Article print

13 Sep 2013 14:15 
Extraordinary Information
Marketing authorisation for biosimilar infliximab in EU
Attached documents:
Releaser: EGIS Pharmaceuticals PLC
Date Issued: 13 Sep 2013
 
Actual
2015 average
Name
Price
%
Turn. (tEUR)
ˇ
921
-1.39
467
^
197
+2.07
11
ˇ
159
-1.24
10
-
7,960
0.00
5
ˇ
21,250
-0.23
2
ˇ
771
-1.03
11
-
2,280
0.00
7
^
14,565
+0.66
895
-
395
0.00
628
ˇ
5,626
-1.28
3,400
ˇ
302
-1.95
8
^
1,174
+0.43
10
ˇ
4,172
-1.37
707
ˇ
89
-3.26
0
Change %: to baseprice
Data delayed by 15 minutes
Indices
Index
Value
Change %
BUX
21,873.78
-131.91 (-0.60)
1,636.01
-8.45 (-0.51)
1,212.59
-1.76 (-0.14)
1,197.90
-2.21 (-0.18)
1,869.23
-1.36 (-0.07)